Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal CancerFausto Petrelli, Alberto F. Sobrero, Roberto Labianca et al.|JAMA Oncology|2020Cited by 49
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trialMaria Di Bartolomeo, Filippo Pietrantonio, Mario Scartozzi et al.|BMC Cancer|2019Cited by 15
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup AnalysisGerardo Rosati, Fabio Galli, Maurizio Cantore et al.|The Oncologist|2020Cited by 11
Phase II randomized study of maintenance therapy with regorafenib (REGO) versus placebo after first-line platinum and fluoropyrimidines-based chemotherapy in HER2 negative locally advanced/metastatic gastric (GC) or gastroesophageal junction (GEJ) cancer: Results of a-MANTRA study (GOIRC-05-2016).Angela Damato, Carmine Pinto, Domenico Bilancia et al.|Journal of Clinical Oncology|2024Cited by 1
Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial.Federica Morano, Maria Di Bartolomeo, Monica Niger et al.|Journal of Clinical Oncology|2019Cited by 0